TRCT
BDTX icon

Tower Research Capital (TRC)’s Black Diamond Therapeutics BDTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4K Buy
9,947
+5,550
+126% +$13.6K ﹤0.01% 3631
2026
Q1 		$9.37K Sell
4,397
-3,999
-48% -$9.51K ﹤0.01% 3931
2025
Q4 		$20.4K Buy
+8,396
New +$29.7K ﹤0.01% 3084
2025
Q3 		– Sell
-21,031
Closed -$52.2K – 5226
2025
Q2 		$52.2K Buy
21,031
+14,410
+218% +$27.8K ﹤0.01% 2934
2025
Q1 		$10.3K Sell
6,621
-1,659
-20% -$3.48K ﹤0.01% 3662
2024
Q4 		$17.7K Sell
8,280
-4,063
-33% -$11.6K ﹤0.01% 3290
2024
Q3 		$53.7K Buy
12,343
+11,303
+1,087% +$61.5K ﹤0.01% 2682
2024
Q2 		$4.85K Sell
1,040
-4,121
-80% -$22.1K ﹤0.01% 4740
2024
Q1 		$26.2K Buy
5,161
+569
+12% +$2.29K ﹤0.01% 2764
2023
Q4 		$12.9K Sell
4,592
-3,258
-42% -$7.64K ﹤0.01% 4003
2023
Q3 		$22.5K Buy
7,850
+5,734
+271% +$21.1K ﹤0.01% 3269
2023
Q2 		$10.7K Sell
2,116
-5,511
-72% -$11.3K ﹤0.01% 4081
2023
Q1 		$15K Buy
7,627
+4,162
+120% +$9.56K ﹤0.01% 3764
2022
Q4 		$6K Sell
3,465
-810
-19% -$1.46K ﹤0.01% 4681
2022
Q3 		$7K Sell
4,275
-180
-4% -$555 ﹤0.01% 4868
2022
Q2 		$11K Buy
4,455
+897
+25% +$2.08K ﹤0.01% 4351
2022
Q1 		$10K Sell
3,558
-7,691
-68% -$28.1K ﹤0.01% 4276
2021
Q4 		$60K Buy
11,249
+8,845
+368% +$61.8K ﹤0.01% 2618
2021
Q3 		$20K Buy
2,404
+457
+23% +$4.51K ﹤0.01% 3697
2021
Q2 		$24K Buy
1,947
+463
+31% +$9.15K ﹤0.01% 3715
2021
Q1 		$36K Sell
1,484
-955
-39% -$25.8K ﹤0.01% 3392
2020
Q4 		$78K Sell
2,439
-11,701
-83% -$384K ﹤0.01% 2588
2020
Q3 		$427K Buy
14,140
+11,644
+467% +$354K ﹤0.01% 1858
2020
Q2 		$105K Buy
+2,496
New +$91.9K ﹤0.01% 2406

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Tower Research Capital (TRC)'s BDTX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Black Diamond Therapeutics (BDTX) stake by 126% in Q2 2026, buying an estimated $13.6K and bringing the position to 9,947 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3631.

Tower Research Capital (TRC) first reported a position in BDTX in Q2 2020 and has held it in 24 quarters since. The position peaked at $427K in Q3 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Tower Research Capital (TRC) held 9,947 shares of Black Diamond Therapeutics worth $18.4K as of Q2 2026.
  • Tower Research Capital (TRC) bought 5,550 Black Diamond Therapeutics shares in Q2 2026, an estimated $13.6K.
  • Black Diamond Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3631 holding.
  • Tower Research Capital (TRC) first reported a position in Black Diamond Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Black Diamond Therapeutics position peaked at $427K in Q3 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.